CagriSema

Novo Nordisk

CagriSema is a single once-weekly injectable that combines two established mechanisms: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist that is already approved for weight management and diabetes as separate products. The concept is that amylin and GLP-1 suppress appetite through complementary pathways, so co-formulating them could deliver greater weight loss than either component alone while keeping to a convenient weekly injection. Novo Nordisk has studied CagriSema in the Phase 3 REDEFINE program in people with obesity and in type 2 diabetes. Reported results have shown substantial weight loss — in the low-to-mid 20% range in the obesity trial — which is meaningful but, in the eyes of many analysts, came in somewhat below the highest pre-trial expectations, partly reflecting how many participants reached the top dose. CagriSema is not approved and remains investigational pending regulatory review; the data continue to be evaluated. It is documented here as a reference on a leading late-stage obesity combination, not as a purchasable product. Because it contains semaglutide plus an amylin analog, its tolerability profile is dominated by gastrointestinal effects during dose escalation, and it should only ever be used within a trial or, if approved, under medical supervision.